NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer

Small cell lung cancer (SCLC) is a high-grade malignancy, and treatment strategies have not changed for decades. In this study, we searched for novel targets for antibody-drug conjugate (ADC) therapy for SCLC. We identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1 (NRXN1). The cell surface overexpression of NRXN1 was confirmed using flow cytometry in SCLC cell lines (SHP77 and NCI-H526). The combination of a primary anti-NRXN1 monoclonal antibody and a secondary ADC exhibited anti-tumor activity in SCLC cell lines. Moreover, the knockout of NRXN1 in SHP77 cells resulted in a loss of the anti-tumor activity of NRXN1-mediated ADC therapy. Thus, NRXN1 could be a novel target for ADC therapy for the treatment of SCLC that is worth further research.

[1]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[2]  A. Deneka,et al.  Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC) , 2019, Cancers.

[3]  J. Arribas,et al.  MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors , 2019, Molecular Cancer Therapeutics.

[4]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[5]  O. Elemento,et al.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer , 2019, Science Translational Medicine.

[6]  Daniel Martinez,et al.  An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma , 2019, Science Translational Medicine.

[7]  A. Iyer,et al.  PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer , 2019, Cancers.

[8]  G. Sica,et al.  Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Groen,et al.  A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors , 2018, Clinical Cancer Research.

[10]  B. Loo,et al.  NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[12]  A. Rajpal,et al.  RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models , 2018, Oncotarget.

[13]  K. Gish,et al.  LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates. , 2018, Cancer research.

[14]  C. Rudin,et al.  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Anu V. Connor,et al.  Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors , 2018, Clinical Cancer Research.

[16]  M. Galanopoulos,et al.  Advanced small cell lung cancer (SCLC): new challenges and new expectations. , 2018, Annals of translational medicine.

[17]  Cécile Chalouni,et al.  Fate of Antibody-Drug Conjugates in Cancer Cells , 2018, Journal of experimental & clinical cancer research : CR.

[18]  Ligong Chen,et al.  Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models , 2017, Oncotarget.

[19]  K. Tabuchi,et al.  Neurexins and neuropsychiatric disorders , 2017, Neuroscience Research.

[20]  R. Heist,et al.  Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan , 2017, Clinical Cancer Research.

[21]  A. Scott,et al.  Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells , 2017, Nature Reviews Clinical Oncology.

[22]  R. Gale,et al.  Gemtuzumab ozogamicin in acute myeloid leukemia , 2017, Leukemia.

[23]  Y. Ishikawa,et al.  Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes , 2017, Oncotarget.

[24]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[25]  Samuel A. Williams,et al.  A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions , 2017, Science Translational Medicine.

[26]  G. Clowry,et al.  Neurexins 1–3 Each Have a Distinct Pattern of Expression in the Early Developing Human Cerebral Cortex , 2016, Cerebral cortex.

[27]  M. Socinski,et al.  Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease , 2017, Clinical lung cancer.

[28]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[29]  Kornel Labun,et al.  CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering , 2016, Nucleic Acids Res..

[30]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[31]  C. Rudin,et al.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.

[32]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[33]  Edmund A. Rossi,et al.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.

[34]  Hidemasa Bono,et al.  CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites , 2014, Bioinform..

[35]  D. Schreiner,et al.  Targeted Combinatorial Alternative Splicing Generates Brain Region-Specific Repertoires of Neurexins , 2014, Neuron.

[36]  Tao Wang,et al.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.

[37]  W. Travis.  Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. , 2014, Thoracic surgery clinics.

[38]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[39]  R. Chari,et al.  Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. , 2014, Journal of medicinal chemistry.

[40]  L. Harlan,et al.  Treatment of Small Cell Lung Cancer in Academic and Community Settings: Factors Associated With Receiving Standard Therapy and Survival , 2014, Cancer journal.

[41]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[42]  D. Takai,et al.  Polymerase reaction without primers throughout for the reconstruction of full-length cDNA from products of rapid amplification of cDNA ends (RACE) , 2011, Biotechnology Letters.

[43]  R. M. Henke,et al.  Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube. , 2009, Developmental biology.

[44]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[45]  M. Missler,et al.  Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components , 2008, Proceedings of the National Academy of Sciences.